PRISM (Proteomic, Inflammatory Response, Mass Spectrometry) Inserm U1192 is a unique worldwide laboratory creating and developing novel health technologies including new diagnostic tools and novel therapies as well as new fundamental biological concepts all turned to personalized & precision medicine.
The mission of PRISM is to better understand the pathophysiology in oncology and neurology and discover new mechanisms to treat them. To achieve this goal PRISM developed an interdisciplinary and trans-disciplinary approach involving physic instrumentation, surface and analytical chemistry, cellular and molecular biology, and clinics. PRISM is based on state-of-the art molecular imaging and multi-omic technologies to give deep analyses for clinics biomarkers diagnosis and prognosis hunting.
PRISM is associated to the Department of Surgery and Cancer of Imperial College London (ICL) through a European Associated Laboratory (LEA LANCET) supported by Inserm and to the Department of Chemistry of Yale as an Inserm-ULille International Research Project (IRP GHOSTGLY).
PRISM has a join laboratory with the OCR company (www.oncovet-clinical-research.com/
). This mixed private/public team (O’DREAMS,
Oncological Driven associated Mass Spectrometry) is financially supported by the Regional Council of Hauts-de-France and EU through FEDER funding. O’DREAMS has led OCR to obtain a support from France Relance 2030 scheme.
PRISM also includes a core facility OrganOmics based on competences derived from technological innovations research of the lab. It includes 2 service platforms, one for mass spectrometry-based proteomics (MS4Omics) and a second one (3DCellOmics) for 3D cell culture models such as complex organoids with immune cells, fibroblast, microbiota or explants for drug efficiency tests and exosome studies such as for development of therapeutic agents or for diagnosis. The platform offers services to compagnies as well as academics. VVEDIT is a new emerging platform in OrganOmics dedicated to genome editing, transgenesis and viral vectors production.
Finally, PRISM developments have led to the creation of two spin-off companies, IMABIOTECH (MS imaging) in 2009 and in 2023 CELEOS (SpiderMass technology). A new spin-off CARMA on CAR-Macrophages biotherapy is under incubation as well.